Cluster randomised trial of a health system strengthening approach applying person-centred communication for the prevention of female genital mutilation in Guinea, Kenya and Somalia.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
04 Jul 2024
Historique:
medline: 5 7 2024
pubmed: 5 7 2024
entrez: 4 7 2024
Statut: epublish

Résumé

There is limited evidence on effective health systems interventions for preventing female genital mutilation (FGM). This study tested a two-level intervention package at primary care applying person-centred communication (PCC) for FGM prevention. A cluster randomised trial was conducted in 2020-2021 in 180 antenatal care (ANC) clinics in Guinea, Kenya and Somalia. At baseline, all clinics received guidance and materials on FGM prevention and care; at month 3, ANC providers at intervention sites received PCC training. Data were collected from clinic managers, ANC providers and clients at baseline, month 3 and month 6 on primary outcomes, including delivery of PCC counselling, utilisation of level one materials, health facility preparedness for FGM prevention and care services and secondary outcomes related to clients' and providers' knowledge and attitudes. Data were analysed using multilevel and single-level logistic regression models. Providers in the intervention arm were more likely to deliver PCC for FGM prevention compared with those in the control arm, including inquiring about clients' FGM status (adjusted OR (AOR): 8.9, 95% CI: 6.9 to 11.5; p<0.001) and FGM-related beliefs (AOR: 9.7, 95% CI: 7.5 to 12.5; p<0.001) and discussing why (AOR: 9.2, 95% CI: 7.1 to 11.9; p<0.001) or how (AOR: 7.7, 95% CI: 6.0 to 9.9; p<0.001) FGM should be prevented. They were more confident in their FGM-related knowledge (AOR: 7.0, 95% CI: 1.5 to 32.3; p=0.012) and communication skills (AOR: 1.8; 95% CI: 1.0 to 3.2; p=0.035). Intervention clients were less supportive of FGM (AOR: 5.4, 95% CI: 2.4 to 12.4; p<0.001) and had lower intentions of having their daughters undergo FGM (AOR: 0.3, 95% CI: 0.1 to 0.7; p=0.004) or seeking medicalised FGM (AOR: 0.2, 95% CI: 0.1 to 0.5; p<0.001) compared with those in the control arm. This is the first study to provide evidence of an effective FGM prevention intervention that can be delivered in primary care settings in high-prevalence countries. PACTR201906696419769 (3 June 2019).

Identifiants

pubmed: 38964796
pii: bmjopen-2023-078771
doi: 10.1136/bmjopen-2023-078771
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e078771

Informations de copyright

© World Health Organization 2024. Licensee BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Mamadou Dioulde Balde (MD)

Centre for Research in Reproductive Health in Guinea, Conakry, Guinea.

Patrick Muia Ndavi (PM)

Department of Obstetrics and Gynecology, University of Nairobi, Nairobi, Kenya.

Vernon Mochache (V)

Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.

Anne-Marie Soumah (AM)

Centre for Research in Reproductive Health in Guinea, Conakry, Guinea.

Tammary Esho (T)

Amref International University, Nairobi, Kenya.

James Munyao King'oo (JM)

Department of Biochemistry and Biotechnology, Technical University of Kenya, Nairobi, Kenya.

Jackline Kemboi (J)

Department of Obstetrics and Gynecology, University of Nairobi, Nairobi, Kenya.

Alpha Oumar Sall (AO)

Centre for Research in Reproductive Health in Guinea, Conakry, Guinea.

Aissatou Diallo (A)

Centre for Research in Reproductive Health in Guinea, Conakry, Guinea.

Wisal Ahmed (W)

United Nations Population Fund, Addis Ababa, Ethiopia.

Karin Stein (K)

Division of Healthier Populations, World Health Organization, Geneva, Switzerland.

Khurshed Nosirov (K)

Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.

Soe Soe Thwin (SS)

Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.

Max Petzold (M)

Public Health and Community Medicine, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden.

Muna Abdi Ahmed (MA)

Central Statistics Department, Ministry of Planning and National Development, Hargeisa, Somaliland, Somalia.

Ahmed Diriye (A)

Data and Research Solutions, Hargeisa, Somaliland, Somalia.

Christina Pallitto (C)

Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland pallittoc@who.int.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH